ClinicalTrials.gg

Program

Osilodrostat

Also written as “LCI699” and “osilodrostat”.

Its studies are mostly in Hypertension · Cushing Syndrome · Adrenocortical Hyperfunction · Pituitary ACTH Hypersecretion · Essential Hypertension, led by 2 companies.

Furthest: phase 4, since Jun 17, 201413 company-led studies, 2 open or runningNext primary completion: Jul 21, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis100 open or runningphase 3since Jun 17, 2014Aug 5, 2008none ahead
RECORDATI GROUP32 open or runningphase 4since Nov 19, 2025Jul 20, 2018Jul 21, 2027phase 2 · NCT03708900

Also a collaborator on its studies: great-lakes-drug-development-inc and integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2008First study: phase 2 study in HyperaldosteronismNew to NovartisNovartis · NCT00732771 · 12 enrolled · France
  2. Sep 23, 2008Phase 2 study in Essential HypertensionNovartis · NCT00758524 · 628 enrolled · United States
  3. Jan 5, 20092 phase 2 studies in HypertensionNovartis · NCT00817635, NCT00817414
  4. Apr 6, 2011Phase 2 study in Adrenocortical HyperfunctionNovartis · NCT01331239 · 31 enrolled · United States, France, Italy and more
  5. Jun 17, 2014Phase 3 study in Adrenocortical HyperfunctionNovartis · NCT02180217 · 137 enrolled · United States, Argentina, Austria and more
  6. Feb 23, 2015Phase 1 study in Hepatic ImpairmentNovartis · NCT02372084 · 33 enrolled · United States
  7. Mar 20, 2015Phase 1 study in Renal InsufficiencyNovartis · NCT02399202 · 15 enrolled · Bulgaria, Germany
  8. Jun 8, 2015Phase 2 study in Cushing SyndromeNovartis · NCT02468193 · 9 enrolled · Japan
  9. Feb 27, 2016Phase 3 study in Pituitary ACTH HypersecretionNovartis · NCT02697734 · 73 enrolled · United States, Belgium, Brazil and more
  10. Jul 20, 2018RECORDATI GROUP's first study: phase 2 study in Cushing SyndromeNew to RECORDATI GROUPRECORDATI GROUP · NCT03606408 · 127 enrolled · United States, Argentina, Austria and more
  11. Oct 8, 2018Phase 2 study in Cushing SyndromeRECORDATI GROUP · NCT03708900 · 12 planned · United States, Belgium, Bulgaria and more
  12. Nov 19, 2025Phase 4 study in HypertensionRECORDATI GROUP · NCT07247162 · 63 planned · United States

Ahead

  1. Jul 21, 2027Primary completion: phase 2 study in Cushing SyndromeRECORDATI GROUP · NCT03708900
  2. May 2028Primary completion: phase 4 study in HypertensionRECORDATI GROUP · NCT07247162

TargetBeta

“An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), ”NCIt, by rule
“Cytochrome P450 11B1 inhibitor”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07247162Hypertension · United States4RecruitingRECORDATI GROUPMay 202863
NCT03708900Cushing Syndrome · United States, Belgium, Bulgaria and more2RecruitingRECORDATI GROUPJul 21, 202712
NCT03606408Cushing Syndrome · United States, Argentina, Austria and more2CompletedRECORDATI GROUPNov 16, 2023127
NCT02697734Pituitary ACTH Hypersecretion · United States, Belgium, Brazil and more3CompletedNovartisJun 19, 201973
NCT02468193Cushing Syndrome · Japan2CompletedNovartisJun 7, 20189
NCT02399202Renal Insufficiency · Bulgaria, Germany1CompletedNovartisMar 21, 201615
NCT02372084Hepatic Impairment · United States1CompletedNovartisMay 19, 201633
NCT02180217Adrenocortical Hyperfunction · United States, Argentina, Austria and more3CompletedNovartisFeb 21, 2018137
NCT01331239Adrenocortical Hyperfunction · United States, France, Italy and more2CompletedNovartisOct 22, 201931
NCT00817635Hypertension · United States, Iceland2CompletedNovartisOct 13, 2009155
NCT00817414Hypertension · United States, Iceland2CompletedNovartisAug 12, 200963
NCT00758524Essential Hypertension · United States2CompletedNovartisJul 2, 2009628
NCT00732771Hyperaldosteronism · France2CompletedNovartisMay 200912

How it is read

Names in the registry

  • “LCI699”, 6 entries
  • “osilodrostat”, 5 entries
  • “Osilodrostat”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.